242 related articles for article (PubMed ID: 26565015)
41. Evaluation of the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Usery JB; Vo NH; Finch CK; Cleveland KO; Gelfand MS; Self TH
Am J Med Sci; 2015 Jan; 349(1):36-41. PubMed ID: 25233042
[TBL] [Abstract][Full Text] [Related]
42. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.
Ahmad NM; Rojtman AD
Ann Pharmacother; 2010 May; 44(5):918-21. PubMed ID: 20354160
[TBL] [Abstract][Full Text] [Related]
43. What do beta-lactams add to vancomycin or daptomycin in the treatment of patients with methicillin-resistant
García Aragonés L; Blanch Sancho JJ; Segura Luque JC; Mateos Rodriguez F; Martínez Alfaro E; Solís García Del Pozo J
Postgrad Med J; 2022 Jan; 98(1155):48-56. PubMed ID: 33563707
[TBL] [Abstract][Full Text] [Related]
44. Duration of prior vancomycin therapy and subsequent daptomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
Culshaw D; Lamp KC; Yoon MJ; Lodise TP
Diagn Microbiol Infect Dis; 2015 Oct; 83(2):193-7. PubMed ID: 26184127
[TBL] [Abstract][Full Text] [Related]
45. Alternative agents to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
Culos KA; Cannon JP; Grim SA
Am J Ther; 2013; 20(2):200-12. PubMed ID: 21642833
[TBL] [Abstract][Full Text] [Related]
46. Successful Conservative Treatment of Mycotic Pulmonary Artery Aneurysms Caused by MRSA Bacteremia.
Iki Y; Hata A; Fukuyama M; Yoshioka T; Watanabe K; Asari S; Hata D
Pediatrics; 2019 Nov; 144(5):. PubMed ID: 31624217
[TBL] [Abstract][Full Text] [Related]
47. Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia.
Gudiol C; Cuervo G; Shaw E; Pujol M; Carratalà J
Expert Opin Pharmacother; 2017 Dec; 18(18):1947-1963. PubMed ID: 29115883
[TBL] [Abstract][Full Text] [Related]
48. Methicillin-resistant Staphylococcus aureus bacteraemia and mortality in a teaching hospital.
Beeston CJ; Gupta R; Chadwick PR; Young RJ
Eur J Clin Microbiol Infect Dis; 2009 Jun; 28(6):585-90. PubMed ID: 19067002
[TBL] [Abstract][Full Text] [Related]
49. Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy.
Kullar R; McKinnell JA; Sakoulas G
Clin Infect Dis; 2014 Nov; 59(10):1455-61. PubMed ID: 25048852
[TBL] [Abstract][Full Text] [Related]
50. Risk factors for mortality in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia in a tertiary care hospital in Taiwan.
Lin SH; Liao WH; Lai CC; Liao CH; Tan CK; Wang CY; Huang YT; Hsueh PR
J Antimicrob Chemother; 2010 Aug; 65(8):1792-8. PubMed ID: 20511366
[TBL] [Abstract][Full Text] [Related]
51. Vancomycin MIC as a predictor of outcome in MRSA bacteraemia in the UK context.
Hope R; Blackburn RM; Verlander NQ; Johnson AP; Kearns A; Hill R; Hopkins S; Sheridan E; Livermore DM; ;
J Antimicrob Chemother; 2013 Nov; 68(11):2641-7. PubMed ID: 23794604
[TBL] [Abstract][Full Text] [Related]
52. A survey of attitudes towards methicillin-resistant Staphylococcus aureus bacteraemias amongst United Kingdom microbiologists.
Hussain A; Alleyne S; Jenkins D
J Antimicrob Chemother; 2010 Feb; 65(2):347-9. PubMed ID: 20008906
[TBL] [Abstract][Full Text] [Related]
53. Serious infections caused by methicillin-resistant Staphylococcus aureus.
Boucher H; Miller LG; Razonable RR
Clin Infect Dis; 2010 Sep; 51 Suppl 2():S183-97. PubMed ID: 20731576
[TBL] [Abstract][Full Text] [Related]
54. Multiple pathways of cross-resistance to glycopeptides and daptomycin in persistent MRSA bacteraemia.
Chen CJ; Huang YC; Chiu CH
J Antimicrob Chemother; 2015 Nov; 70(11):2965-72. PubMed ID: 26216581
[TBL] [Abstract][Full Text] [Related]
55. Adjuvant β-Lactam Therapy Combined with Vancomycin or Daptomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: a Systematic Review and Meta-analysis.
Wang C; Ye C; Liao L; Wang Z; Hu Y; Deng C; Liu L
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32839217
[TBL] [Abstract][Full Text] [Related]
56. Early appropriate therapy of Gram-positive bloodstream infections: the conservative use of new drugs.
Grossi PA
Int J Antimicrob Agents; 2009; 34 Suppl 4():S31-4. PubMed ID: 19931814
[TBL] [Abstract][Full Text] [Related]
57. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
[TBL] [Abstract][Full Text] [Related]
58. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
Moore CL; Osaki-Kiyan P; Haque NZ; Perri MB; Donabedian S; Zervos MJ
Clin Infect Dis; 2012 Jan; 54(1):51-8. PubMed ID: 22109947
[TBL] [Abstract][Full Text] [Related]
59. Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Kullar R; Davis SL; Kaye KS; Levine DP; Pogue JM; Rybak MJ
Pharmacotherapy; 2013 Jan; 33(1):3-10. PubMed ID: 23307539
[TBL] [Abstract][Full Text] [Related]
60. Empirical antimicrobial therapy for bloodstream infection due to methicillin-resistant Staphylococcus aureus: no better than a coin toss.
Herzke CA; Chen LF; Anderson DJ; Choi Y; Sexton DJ; Kaye KS
Infect Control Hosp Epidemiol; 2009 Nov; 30(11):1057-61. PubMed ID: 19803766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
